Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|September 2, 2013
- Pharmaceutical Technology-09-02-2013
- Volume 37
- Issue 9
XstalBio Introduces CentuRecon
CentuRecon enables dry formulations of therapeutic proteins to quickly be prepared for injection at high concentration.
CentuRecon, a patented reconstitution technology, decreases the preparation time of high concentration protein solutions from dry powder formulations and makes delivery faster and safer, according to the company. CentuRecon enables dry formulations of therapeutic proteins to quickly be prepared for injection at high concentration and produces foam-free solutions that maximize the deliverable dose. CentuRecon is compatible with standard lyophilized formulations and diluents and with normal vials, cartridges, or dual-chamber syringes. It can be used for very high concentration and/or viscous solutions that may need to be delivered with injection devices.
Articles in this issue
about 13 years ago
The Importance of Continued Investment in R&Dabout 13 years ago
FDA Works to Secure Drug Supply Chainabout 13 years ago
Outsourcing Partnerships for CMC Developmentabout 13 years ago
MF40 Automated Punch and Die Polishing Machineabout 13 years ago
Quality by Design in APIsabout 13 years ago
Connecting People, Science, and Regulationabout 13 years ago
Effective and Efficient Weighing of Potent Compoundsabout 13 years ago
EU Raises API Standards: A Curse in Disguise?about 13 years ago
The Importance of Characterization in Biosimilars Developmentabout 13 years ago
Omega Design Corporation Introduces LabelSync 450Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5